GOLM1 and prostate cancer: Liu et al (2006) described GOLPH2 mRNA as overexpressed by a fold change of 3.14 in their samples (13 normal; 45 cancer), which did not correlate to tumour differentiation according to GS. A comprehensive analysis of the studies from Oncomine combining 260 samples from CaP and 135 from benign prostate normal revealed an overexpression of GOLPH2 by a factor of 2.7 in prostate cancer (P<0.001, Figure 1A).